Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis

作者全名："Zhao, Ruiqiu; Long, Xiaoru; Wang, Jiangxia; Zhu, Jing; Liu, Cong; Shang, Tingting; Zhang, Zhenzhen; Obi, Engels; Osadebe, Lynda; Kang, Yue; Liu, Jie; Chen, Xiaodi; Xu, Hongmei"

作者地址："[Zhao, Ruiqiu; Long, Xiaoru; Wang, Jiangxia; Zhu, Jing; Liu, Cong; Shang, Tingting; Zhang, Zhenzhen; Xu, Hongmei] Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Chongqing Key Lab Pediat,Key Lab Child, Chongqing, Peoples R China; [Obi, Engels; Osadebe, Lynda] Merck & Co Inc, Rahway, NJ USA; [Kang, Yue; Liu, Jie; Chen, Xiaodi] MSD China, MRL Global Med Affairs, Shanghai, Peoples R China"

通信作者："Xu, HM (通讯作者)，Chongqing Med Univ, Childrens Hosp, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Chongqing Key Lab Pediat,Key Lab Child, Chongqing, Peoples R China."

来源：FRONTIERS IN PEDIATRICS

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000880193100001

JCR分区：Q1

影响因子：2.6

年份：2022

卷号：10

期号：　

开始页：　

结束页：　

文献类型：Review

关键词：children; infection; ertapenem; efficacy; safety

摘要："Objectives: To assess and summarize current evidence on the effectiveness and safety of ertapenem for treatment of childhood infections, in consideration of high infection prevalence in children and wide use of ertapenem. Methods: The following 8 databases were searched on 13th May 2021: Web of Science, Embase via Ovid SP, PubMed, The Cochrane Library (CENTRAL), Chinese BioMedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), VIP and Wanfang. The primary outcome was treatment success rate. Risk ratios (RRs) and 95% confidence interval (CI) were estimated using random-effect models. Subgroup analysis was conducted where heterogeneity was found. Results: Fifteen studies (8 randomized controlled trials, 1 observational comparative study, and 6 before and after studies) involving 2,528 patients were included in the final review. Ertapenem had similar treatment success rates with beta-lactam antibiotics [relative risk (RR) = 1.08, 95% CI: 0.99-1.19]. In a subgroup analysis, similar efficacy (RR = 1.08, 95% CI: 0.97-1.20) between ertapenem and other carbapenems. Compared with beta-lactam antibiotics, ertapenem did not increase the risk of any adverse events (RR = 1.02, 95%CI: 0.71-1.48), drug-related diarrhea (all non-Asian children, RR = 0.62, 95%CI: 0.31-1.25), or injection site pain (all non-Asian children, RR = 1.66, 95%CI: 0.59-4.68). Subgroup analysis showed no obvious difference between ertapenem group and carbapenems or non-carbapenems group on risk of adverse events. Conclusion: Our findings suggest that ertapenem is effective and safe in treatment for children with infection. Further comparative real-world data is needed to supplement clinical evidence on the overall benefits of ertapenem in this population."

基金机构：MSD China

基金资助正文：This research was funded by the MSD China.